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ABSTRACT
Introduction: The treatment of acute coronary syndromes, besides coronary interventions, includes pharmaco-
therapy and lifestyle changes, which together determine a favourable prognosis. Adherence to treatment is a 
term describing a patient’s behaviour in respect to the patient’s maintenance of the health care provider’s 
recommendations. Unfortunately, according to WHO data, adherence to long-term therapies for chronic 
illnesses in developed countries averages only 50%. 
Covered areas: Our study focused on available questionnaires for adherence assessment in everyday practice. 
A comprehensive search of data bases was conducted using appropriate keywords. Out of an initially 
identified 2081 citations, 93 articles were considered eligible for further analysis. Eventually, nine adherence 
scales were identified and reviewed. 
Expert opinion: There is no so-called “gold standard survey” allowing accurate assessment of every patient for 
medication adherence. The use of a specific scale must be justified by its validation in a similar group of 
patients in well designed and properly conducted studies.
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Introduction
Cardiovascular diseases are the main cause of 
death worldwide [1,2], and the number of adults with 
diagnosed chronic heart failure is increasing system-
atically [3]. In particular, the rate of acute coronary 
syndromes in developed countries remains high [4]. 
The treatment of acute coronary syndromes, as well as 
coronary interventions, includes pharmacotherapy and 
lifestyle changes, which together determine a favour-
able prognosis [5–7]. According to data available in the 
literature, only 8% of patients after myocardial infarction 
follow medical staff recommendations from their health 
care givers [8–12]. To systematise the phenomenon 
of following the medical recommendations, the term 
“adherence” is used. The World Health Organisation 
(WHO) defines “adherence” as “the extent to which 
a person’s behaviour including taking medication, 
following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from 
a health care provider” [13]. According to Food and 
Drug Administration data, from 30 to 50% of patients 
do not strictly adhere to recommendations received 
from their healthcare providers, which significantly 
increases the risk of death [14–17]. The enhancement 
of adherence to medication is usually accompanied by 
elimination of unfavourable dietary habits and increased 
physical activity [18–22]. 
There are direct and indirect methods of adherence 
assessment; however, it seems impossible to point out 
one as clearly the best tool for measurement [23–26]. 
Observation of the treatment process and plasma 
concentrations of the medication or its metabolites, as 
well as biological markers, are proposed as direct meth-
ods allowing the assessment of adherence [27–30]. 
The indirect methods include: questionnaire surveys, 
analysis of pharmacy registers, the use of electronic 
devices measuring medication intake (e.g. containers 
registering time and frequency of taking medications), 
clinical observation of patients, and assessment of the 
progress of illness or its termination [25]. However, low 
reliability of patient self-reports with respect to adher-
ence to health care recommendations as well as the 
potential costs of further verification of collected data 
are responsible for difficulties in the indirect assessment 
of adherence [31–33]. 
116
Medical research journal 2017, vol. 2, no. 4
www.journals.viamedica.pl/medical_research_journal
A systematic investigation of all published literature 
was conducted. We followed the PRISMA statement for 
reporting systematic reviews in health care interventions 
[34]. A database search including PubMed without time 
limitations was conducted by two independent investiga-
tors (AKo and KB). The following keywords were applied: 
“medication adherence assessment” or “questionnaire” 
or “survey” or “scale”. References of retrieved studies 
were searched manually for additional studies and re-
views. No language restrictions were applied. Data were 
abstracted on prespecified forms. All divergences were 
resolved by discussion with a third investigator (AKu). 
After a systematic search, 2081 citations were identified. 
Duplicate / multiple citations and reviews containing no 
relevant information were excluded. Eventually, 93 articles 
were considered eligible for further analysis, and nine ad-
herence scales dedicated for patients with cardiovascular 
diseases were identified and reviewed (Table 1).
The aim of the study was to present available ques-
tionnaire-based methods of adherence assessment in 
patients with cardiovascular diseases. 
Morisky Medication Adherence Scales 
(MMAS-4 and MMAS-8)
The most popular scale applied for the assessment 
of adherence is the MMAS. It is a quick and simple tool 
used by health care professionals [35]. The original 
Morisky scale published in 1986 has four items that have 
dichotomous response categories with yes or no [36]. 
The authors of this scale assumed that low adherence 
is mainly due to insufficient care, lack of accuracy, and 
forgetting. Moreover, patients modify doses of medica-
tions according to their changeable well-being as well 
as their daily plans (e.g. leaving medications at home 
while traveling). The MMAS-4 was quite an innovative 
diagnostic tool at the time of its introduction due to its 
identification of the fundamental reasons for non-adher-
ence to medication. However, it did not show optimal 
psychometric properties. The sensitivity and specificity 
were 81% and 44%, respectively, with the Cronbach’s 
alpha reliability of 0.61, which is below the acceptable 
value of 0.7. Despite fair psychometric characteristics, 
MMAS-4 is still in use [36]. 
The MMAS-4 differentiates whether the nonadher-
ence is intentional or unintentional. The first two items 
refer to the unintentional non-adherence to treatment 
due to forgetfulness and carelessness. The last two 
items concern the intentional cessation of medication 
when feeling better or worse [37–38] 
In 2008 the modified eight-item scale (MMAS-8) was 
developed to overcome the limitations of MMAS-4 [36]. 
The first seven items are dichotomous response catego-
ries with yes or no, and the last item inquires how often 
the responder misses the daily doses of medications, 
with five response options and corresponding different 
scoring. The MMAS-8 has much better psychometric 
properties with sensitivity and specificity of 93% and 
53%, respectively, and Cronbach’s alpha value of 
0.83. Moreover, the addition of four items allows us to 
identify and address the circumstances or situations 
related to adherence behaviour [36].
Validation of the scale was performed on a large 
number of patients with various chronic illnesses, in-
cluding hypertension, hypercholesterolaemia, diabetes 
mellitus type 2, depression, Parkinson’s disease, heart 
failure, coronary artery disease, and HIV [39–41]. 
Table 1. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases
No. Questionnaire Year  
of introduction
Original  
language
Population in initial 
validation study
Internal 
consistency
Cronbach’s a
1 MMAS-4 1986 English Hypertension 0.61
2 MMAS-8 2008 English Hypertension 0.83
3 SEAMS 2007 English Coronary artery disease 
with comorbidities
0.89
4 HBCS 2000 English Hypertension 0.79
5 BMQ 1999/2012 English/Portuguese Hypertension n.a./0.66
6 ACDS 2016 Polish Coronary artery disease 
with previous myocardial 
infarction
0.75
7 TAQPH 2012 Chinese Hypertension 0.86
8 MBG 2008 Spanish Hypertension 0.89
9 ASRQ 2008 English Hypertension n.a.
Morisky Medication Adherence Scale (MMAS); Self-efficacy for Appropriate Medication Use (SEAMS); Hill - Bone Compliance Scale (HBCS); 
Brief Medication Questionnaire (BMQ); Adherence in Chronic Diseases Scale (ACDS); Treatment Adherence Questionnaire for Patients with 
Hypertension (TAQPH); Martin-Bayarre-Grau questionnaire (MBG); Adherence Self-Report Questionnaire (ASRQ)
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The advantages of this scale are: the easiness of 
its application, widespread use in different diseases 
and populations, and concordance with pharmacy fill 
data or electronic monitoring devices. Furthermore, it 
is easy to understand and feasible to apply among dif-
ferent groups of patients, even during everyday visits. It 
works well for the assessment of the level of adherence 
to medications in patients suffering from hypertension 
or coronary artery disease [3,42–45]. However, it does 
not allow a comprehensive assessment of adherence 
behaviours because this scale does not provide ad-
equate information regarding factors contributing to 
non-adherence to medication [42]. 
Thus, the Morisky scale can serve as a screening 
and monitoring tool to identify those patients with 
cardiovascular diseases who might have medication 
adherence problems, but the possibilities of developing 
interventions aimed at improving adherence on the 
basis of the results of this scale are limited [46–49]. 
This was supported by the observation by Sakthong 
et al. [47], who reported a lack of association of blood 
glucose concentration with Morisky scale score in 
diabetic patients. 
Self-efficacy for Appropriate Medication 
Use (SEAMS)
The tool was created by Risser et al., who dealt with 
issues concerning health awareness. It is based on the 
social-cognitive theory of Bandura [50]. The authors 
assumed that patients’ confidence in self effectiveness 
as well efforts aimed at achieving the desired result 
may improve adherence [50–51]. The psychometric 
characteristics were verified in a group of 436 patients 
with coronary artery disease and concomitant diseases 
such as diabetes, hypertension, and hypercholestero-
laemia. The primary version of this scale consisted of 
21 questions, but finally the number was limited. The 
final 13-item scale had good internal consistency reli-
ability (Cronbach’s alpha = 0.89). A two-factor solution 
was found, explaining 52.3% of the scale’s variance. The 
scale was recognised as a reliable and useful tool for 
the assessment of patient self-efficacy in chronic illness 
treatment. The SEAMS scale can be used successfully 
in patients having difficulties with reading and writing. 
This scale aims to identify barriers preventing a high 
level of adherence. Unfortunately, it is time-consuming, 
and this fact is considered to be its main disadvan-
tage. This questionnaire evaluates three fundamental 
elements: patient self-efficacy for appropriate use of 
recommended medications, completeness of recom-
mended pharmacotherapy, and lifestyle changes. The 
patient chooses one answer from three possibilities in 
a three-level Likert scale, where 1 means “I’m not sure”, 
2 “quite sure”, and 3 “completely sure” [39,50].
Hill-Bone Compliance Scale (HBCS)
This is a scale created for patients with hypertension. 
According to WHO data, over 50% of hypertensive 
patients do not take their medications in accordance 
with recommendations. It remains an important issue in 
many countries and explains why the Hill- Bone Com-
pliance Scale was translated into numerous languag-
es. The scale was created as a quick and simple tool 
allowing evaluation of adherence [33,52–53]. It indicates 
possible barriers to adherence and patient self-efficacy. 
This tool evaluates three significant elements of hyper-
tension therapy. It is based on three subscales, each 
consisting of fourteen elements. They cover issues 
concerning the reduction of salt supply in daily diet, ad-
herence to the scheduled visits, and medication-taking 
pattern. The answers describing the frequency of the 
elements mentioned above were incorporated from the 
Likert Scale and include answers as follows: “never”, 
“sometimes”, “mainly”, and “all the time”, with following 
additional options to choose from such as: “doesn’t 
apply” and “I don’t know”. This scale was validated 
among hypertensive patients in South Africa, where this 
disease is very common but insufficiently diagnosed 
and often ignored by primary health care [52]. The 
authors compared results obtained from studies on 
black populations of urban areas covered by the primary 
health care system with results from patients hospital-
ised in internal medicine departments. The comparison 
was conducted among representatives of two ethnic 
groups, labelled in the study as “Black South Africans” 
and “African Americans”. The validation procedure 
showed reasonable internal consistency (standardised 
Cronbach’s alpha of 0.79), with an average inter-item 
correlation of 0.26. In addition, the modified scale had 
significant predictive validity in that noncompliance 
predicted higher diastolic blood pressures (p = 0.21, 
p < 05) and medication noncompliance tended to pre-
dict higher systolic blood pressures (p = 0.20, p < 06). 
The researchers concluded that many behaviours 
strictly connected with hypertension treatment, such 
as application of medications, adherence to medical 
appointments, and reduction of salt supply in the diet, 
are similar in particular ethnic groups. They also con-
firmed that their scale may be successfully used in the 
daily clinical setting. Importantly, this tool requires iden-
tification and differentiation of non-adherent patients 
from non-responders to the applied treatment [52,54]. 
A study including 353 outpatients aimed to compare 
the psychometric characteristics of HBCS to the High 
Blood Pressure Therapy Scale versus Morisky Scale, 
and showed contradictory results of the scales in every 
third patient. For this reason, it is not recommended to 
use both tools at the same time [52]. The HBCS was 
also validated by other researchers from Turkey, after its 
adaptation to the Turkish primary care conditions [55].
118
Medical research journal 2017, vol. 2, no. 4
www.journals.viamedica.pl/medical_research_journal
Brief Medication Questionnaire (BMQ)
This tool is used for the assessment of adherence to 
medication. It also simultaneously indicates limitations 
related to the accomplishment of the therapeutic plan. 
The questionnaire was developed by Svarstad et al. 
[56]. The authors’ intention was to create a short and 
sensitive tool for in-office identification of various causes 
of nonadherence in patients treated with angiotensin 
convertase inhibitors (enalapril or captopril). The form 
includes five questions concerning the prescribed 
pharmacotherapy. The first question verifies whether 
a patient brings his/her medications with him/her to the 
medical appointment. In the second question the patient 
is obliged to give the doses of the prescribed medica-
tions, and in the third question, by filling out a table, the 
patient is asked to write the names of the recommended 
drugs. Furthermore, the survey determines whether 
the patient has interrupted the therapy within the last 
six months. In the fifth, and last, question the patient 
is required to give the name of a medication that was 
not taken systematically and indicate the reason for its 
interruption. Although the questionnaire comprises only 
five questions, an appropriate combination of closed 
and open questions provides a broad picture of patient 
adherence. Properly selected questions allow us to eval-
uate patient knowledge of the recommended therapy 
and identify the obstacles in its observance. Using the 
BMQ, the authors identified low adherence in 48.1% of 
patients [56]. The assessment of the patient’s clinical 
profile alone (including the results of the laboratory 
tests, increased blood pressure, and self-assessment 
of the health state) was recognised as insufficient for 
identification of low adherence [56]. These observations 
led to further exploration of more objective methods of 
adherence assessment. The creation of the BMQ was 
a response to the need of hypertension therapy evalua-
tion. This questionnaire was found to be useful for iden-
tification of patients who demand additional education, 
pharmaceutical support, or verification of the therapy 
plan [56]. This form, together with the Portuguese ver-
sion of the Morisky-Green Test (MGT), was successfully 
used among patients with hypertension and diabetes in 
Southern Brazil [57]. The validation procedure was per-
formed in 206 hypertensive patients attending primary 
healthcare. The tests showed good internal consistency 
by Cronbach’s alpha = 0.66 (95%CI 0.60 to 0.73). The 
BMQ had a sensitivity of 77%, specificity of 58%, and 
an area under the ROC curve of 0.70 (95%CI 0.55 to 
0.86). The correlation between the BMQ and the MGT 
was relatively low r = 0.28, p > 0.001. 
Low adherence per the BMQ was associated with 
higher blood pressure levels when compared to ad-
herent patients (148.4 [SD 20.1] vs. 128.8 [SD 17.8]; 
p < 0.001), but not for the MGT. It was demonstrated 
that the BMQ is significantly more effective among pa-
tients with uncontrolled hypertension [57]. The scale 
was also successfully used in patients with diabetes, 
depression, and other chronic illnesses [58–59].
Adherence in Chronic Diseases Scale 
(ACDS)
Recently Buszko et al. [60] published an article 
validating a new tool for adherence assessment. 
The ACDS questionnaire, created by A. Kubica, was 
designed to examine chronically ill adult patients. It 
allows the assessment of adherence itself, as well 
as identification of the most important factors influ-
encing adherence, such as: acceptance of a therapy 
plan, cooperation between a patient and health care 
professionals, and the economic status of a patient 
[61–63]. The scale’s validation was performed in 
a group of 413 patients with coronary artery disease 
[60]. Originally, the survey included eight questions 
with five possible answers. Four questions (No. 1, 
3, 4, 5) concern the regularity of taking medications 
in prescribed doses, one question (No. 6) concerns 
acceptance of the provided therapy, while the last two 
questions (No. 7 and 8) refer to the patient-physician 
cooperation. The second question, referring to the 
assessment of the treatment-related financial burden, 
was finally removed due to insufficient cohesion with 
the other components of the questionnaire [60]. The 
result is a sum of all gained points. 
In the original version of ACDS, possible scores 
ranged from 0 to 32. Results below 24 points matched 
low adherence, while results of 24-28 points and above 
29 points corresponded to medium and high adher-
ence, respectively. The removal of the second question 
from the survey resulted in new centile distribution and 
reduced the spectrum of results to a range from 0 to 
28 points. This time, results below 21 points, between 
21–26 points, and above 26 points correspond, respec-
tively, to low, medium, and high adherence. The internal 
consistency of the ACDS final version was assessed 
using Cronbach’s alpha coefficient, and the value of 
0.752 confirmed high reliability and homogeneity of the 
questionnaire [60]. 
The ACDS was subsequently applied in a sin-
gle-centre, prospective, observational cohort clinical 
study with a six-month follow-up [64]. In a popula-
tion of 221 patients with myocardial infarction treat-
ed with PCI, lower scores for both of these ACDS 
items were associated with increased risk of acute 
coronary syndrome during follow-up (for item 2: 
3.11 ± 0.68 vs. 3.45 ± 0.73; p = 0.02, and for item 3: 
3.28 ± 0.89 vs. 3.64 ± 0.64; p = 0.04), indicating pre-
dictive value of these items. A high level of adherence 
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(ACDS score >26 points) was found in only 11.1% of 
patients who experienced acute coronary syndrome 
during follow-up versus 28.4% of subjects remaining 
free of this adverse event [64]. 
The scale is simple to use and may be applied 
in everyday medical practice and for research pur-
poses [64–65]. The ability to assess the attitudes 
and behaviour of patients including the essential 
elements of the treatment process should be high-
lighted as strengths of this scale. [60]. The ASCD 
is available for free on the website of the Faculty 
of Health Science of the Nicolaus Copernicus Uni-
versity, Collegium Medicum (http://www.cm.umk.
pl/wydzialy/wydzial-nauk-o-zdrowiu/jednostki-wydzia-
lowe/katedra-i-zaklad-promocji-zdrowia.html).
Treatment Adherence Questionnaire for 
Patients with Hypertension (TAQPH)
Ma et al. [66] developed and tested the Treatment 
Adherence Questionnaire for Patients with Hypertension 
(TAQPH). The TAQPH consists of six subscales with 
28 items. It is a measure dedicated for hypertensive pa-
tients allowing complete adherence evaluation including 
medication and lifestyle changes. The questionnaire 
was tested in a sample of 278 hypertensive patients in 
Guangdong Province of China, explaining 62.54% of the 
total variance in the data. Confirmative factor analysis 
supported a good overall fit of the six-factor model. The 
Cronbach’s alpha coefficient of the overall questionnaire 
was 0.86 and 0.82 for test-retest reliability. The authors 
concluded that the TAQPH can be applied for research 
and clinical purposes [66].
Martin-Bayarre-Grau Questionnaire 
(MBG)
The Martin-Bayarre-Grau, a Spanish language 12-
item questionnaire, was validated in Cuba in a popu-
lation of 114 hypertensive patients. The Cronbach’s 
alpha coefficient of internal consistency was 0.889 for 
the sample [67]. The second validation was performed 
in 142 patients with hypertension, with a Cronbach’s 
alpha value of 0.694 [68]. Validation results showed 
that the formulation of items was reasonable, clear-
ly defined, and justified. The validation procedures 
allowed recognition of the existence of three factors: 
active adherence, autonomy in the face of treatment, 
and adherence complexity, all of which accounted for 
68.7% and 63.4% of observed variance, respectively 
[67–68]. The favourable results of validation support 
the use of MBG in the field of research and medical 
practice. 
Adherence self-report questionnaire 
(ASRQ)
Zeller et al. [69] evaluated a brief adherence self-re-
port questionnaire (ASRQ) in 239 patients with hyper-
tension using a medical event monitoring system, as the 
gold standard comparator. The main outcome measure 
was “timing adherence” (correct inter-dose intervals). 
Patients were asked to choose one of six descriptions 
(from level 1 = perfect adherence to level 6 = nonadher-
ence) to express their medication taking at the end of the 
four-week study period. Most of the evaluated patients 
(89%) stated perfect or nearly perfect adherence, and 
data from the electronic monitors showed a mean timing 
adherence of 88.3% (n = 216). Using the cutoff of those 
who reported ASRQ levels 1 and 2, a high percentage 
of those with comparatively high adherence according 
to MEMS were correctly identified (specificity, 90-93%; 
negative predictive value, 66–96%). However, sensitivity 
(detection of true non-adherers) and positive predictive 
value were poor to moderate (14–42% and 22–66%, 
respectively). According to these results the ASRQ was 
judged as a useful aid to facilitate the difficult differen-
tiation between nonadherence and nonresponse to 
prescribed antihypertensive medication [69].
Expert opinion 
Adherence to treatment and active participation of 
the patient in the therapeutic process not only is benefi-
cial for particular individuals, but also carries economic 
benefits of a social dimension [70–72]. Considering that 
approximately half of the patients requiring treatment 
due to chronic disease do not adhere to the therapeutic 
plan, the assessment of patient adherence to treatment 
plays a pivotal role in the description and verification 
of the therapeutic process [43–44,73–75]. Thus, the 
search for available tools for adherence assessment as 
well as evaluation of their characteristics is necessary 
[76–78]. 
Several different scales evaluating adherence to 
treatment in patients with cardiovascular diseases have 
been developed. The Morisky Medication Adherence 
Scale (MMAS) is a short and easy survey identifying 
barriers to treatment adherence. So far, this is the most 
extensively studied scale, validated for a large number 
of diseases [35–49]. The Self-efficacy for Appropriate 
Medication Use (SEAMS) [50–51], the Hill-Bone Compli-
ance Scale [52–55], the Brief Medication Questionnaire 
(BMQ) [56–59], the Treatment Adherence Questionnaire 
for Patients with Hypertension (TAQPH) [66], the Mar-
tin-Bayarre-Grau questionnaire (MBG) [67–68], and 
the Adherence Self-Report Questionnaire (ASRQ) [69] 
focus on patients with chronic cardiovascular diseases, 
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mainly with hypertension. The Adherence in Chronic 
Diseases Scale (ACDS) is also designed for examining 
chronically ill, adult patients; however, it was validated 
and subsequently applied only in patients after myo-
cardial infarction. It allows assessment of adherence 
itself, as well as identification of the most important 
factors influencing adherence, such as: acceptance 
of a therapy plan and cooperation between the patient 
and health care professionals [60–65]. 
The use of well-built questionnaires should allow 
effective identification of patients characterised by low 
adherence to treatment. Moreover, the knowledge of 
reasons of this phenomenon as well as identification of 
barriers and problems in cooperation between patients 
and health care professionals is crucial for implementa-
tion of tailored educational interventions [79–82]. 
There is no gold standard, nor a universal tool which 
could evaluate the level of adherence. Questionnaires 
may be used as a screening method to identify patients 
with a higher risk of low adherence. An advantage 
of questionnaires is the simplicity of the method and 
easiness of its application. However, selection of a tool 
with optimal characteristics for a particular population 
can be difficult [83–86]. Thus, a guide facilitating the 
choice of an appropriate scale is of great practical 
value. Each of the questionnaires is population-specific 
and was validated in separate populations of patients, 
precluding their deliberate application for adherence 
evaluation in other clinical settings than the originally 
validated ones [85–86]. The lack of a head-to-head 
comparison of questionnaires applicable for the same 
clinical setting, according to their characteristics, is 
a significant shortcoming, precluding indication of an 
optimal tool. In such situations the contents, complexity 
or simplicity, and additional information contained in the 
questionnaires should determine the choice of the most 
adequate scale for the purpose defined by the user. 
Despite all weaknesses of the questionnaires ap-
plied for the assessment of adherence to treatment in 
large-scale studies and in clinical practice, the ease of 
use of this method and its low cost determines contin-
uation of investigations aimed at improving the existing 
tools or  development of new ones tailored for specific 
groups of patients [84,87]. There is an urgent need for 
prospectively conducted studies aimed at careful and 
standardised evaluation of the relevance, reliability, 
consistency, sensitivity, and specificity of the available 
scales in different clinical settings, to ensure identifi-
cation of optimal research and a clinically applicable 
tool [88–90]. A medication adherence scale should 
be able to accurately capture the beliefs, barriers, and 
behaviours related to medication adherence [86,91]. 
Moreover, it should also be easy to apply.
 
Significantly, 
clinicians or researchers should be cautious before 
using them as medication measurements and should 
consider two key points: 1) whether the adherence 
scale is appropriate for use in order to reach the goal 
of the study or an intervention; and 2) if the adherence 
scale is validated in this specific situation, which may 
be distinct from the original setting of validation [92–93]. 
Conclusions
Medication adherence scales are a subjective 
measure of medication adherence, used for studies 
conducted in different patient populations with various 
disease conditions. Many of the adherence scales are 
validated and compared against an objective measure 
of medication adherence. The use of a specific scale 
must be justified by its application and validation in 
a similar group of patients in well designed and properly 
conducted studies. 
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